FDA clears targeted cholangiocarcinoma therapy
-
By
-
Kathryn Wighton
-
September 24, 2026
-
2 min
By
Kathryn Wighton
September 24, 2026
Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.
September 28, 2026
In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.
September 8, 2026
Phase 3 SURPASS ET data showed higher durable response rates with ropeginterferon alfa-2b-njft than with anagrelide.
September 1, 2026